A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer’s disease

A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer’s disease

Trial registration ClinicalTrials.gov Identifier: NCT05821153, Registered April 20 2023, Retrospectively registered, https://classic.clinicaltrials.gov/ct2/show/NCT05821153

Bibliographic Details
Main Authors: Alireza Faridar, Abdulmunaim M. Eid, Aaron D. Thome, Weihua Zhao, David R. Beers, Maria B. Pascual, Mohammad O. Nakawah, Gustavo C. Roman, Charles S. Davis, Michael Grundman, Joseph C. Masdeu, Stanley H. Appel
Format: Article
Language:English
Published: BMC 2023-11-01
Series:Translational Neurodegeneration
Online Access:https://doi.org/10.1186/s40035-023-00387-5

Internet

https://doi.org/10.1186/s40035-023-00387-5

Similar Items